On 21 March 2018, orphan designation (EU/3/18/2001) was granted by the European Commission to Soligenix UK Ltd., United Kingdom, for recombinant modified ricin toxin A-chain subunit (also known as RiVax) for the prevention of ricin poisoning.

Key facts

Active substance
Recombinant modified ricin toxin A-chain subunit
Disease / condition
Prevention of ricin poisoning
Date of decision
Orphan decision number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Soligenix UK Ltd.
Vision Park
Chivers Way
Cambridge CB24 9AD
United Kingdom
Tel. +44 141 582 1211

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating